Indirect process of marking of monoclonal or polyclonal antibodies associated with immunological disorders with radionuclu00ecdeos,In vitro diagnostic reagent or in vitro the basis of monoclonal antibodies or polyclonal marked with radionuclu00ecdeos, use of the reagent for diagnosis.Diagnostic method in vitro and in vivo immunological processes and kit for diagnosis of immunological processes.

摘要

"Indirect process of marking of monoclonal or polyclonal antibodies associated with immunological disorders with radionuclu00ecdeos,Diagnostic reagent for in vivo or in vitro the basis of monoclonal antibodies or polyclonal marked with radionuclu00ecdeos, use of the reagent for diagnosis.Diagnostic method in vitro and in vivo immunological processes and kit for diagnosis of immunological processes.The present invention relates to the appointment, by the indirect method, monoclonal antibodies or polyclonal antibody, especially the Monocional OKT3, with radionuclides, in particular the technetium-99m.The present invention relates to medical and veterinary aiming at the evaluation of immunological processes such as cancer, infectious diseases, autoimmune diseases, inflammation,Transplants, particularly rheumatoid arthritis and renal transplantation.It was developed a simple method for marking indirect monoclonal or polyclonal antibodies, in particular the monoclonal antibody OKT3, with radionuclides, particularly the technetium-99m.It provides high efficiency of marking, and does not change its imunorreatividade, with low cost and short time for preparation.The marking of polyclonal or monoclonal antibodies, in particular the OKT3 with radionuclides, in particular the technetium-99m using a reducing agent.In particular, stannous chloride and a chelating agent, in particular the 2-mercaptoethanol.The monoclonal antibody or policional, particularly the OKT3 is incubated for ten minutes with the chelating agent, especially the 2-mercaptoethanol.The reducing agent, in particular the stannous chloride is added to the solution, and is carried on a new incubation for 10 minutes.Subsequently, the radionuclide is added, in particular the tecnu00e9cio99m with activity of 10 MCI and incubated for another 20 minutes.The final solution is then filtered with a millipore 0.45 109 for withdrawal of technetium-99m colloid free or possible for further application in vitro or in vivo.The quality control is done by chromatographic tests and eletroforu00e9ticos.